Transcatheter aortic valve replacement for pure aortic valve regurgitation: “on-label” versus “off-label” use of TAVR devices
Bernhard Wernly(Paracelsus Medical University), Alexander Lauten(German Centre for Cardiovascular Research), Eliano Pio Navarese(Nicolaus Copernicus University), Volkmar Falk(ETH Zurich), Christian Jung(Heinrich Heine University Düsseldorf), Marcus Franz(Jena University Hospital), Brunilda Alushi(German Centre for Cardiovascular Research), Uta C. Hoppe(Baker Heart and Diabetes Institute), Christian Datz(Paracelsus Medical University), Frederik Beckhoff(German Centre for Cardiovascular Research), Ulf Landmesser(Deutsches Herzzentrum der Charité), Michael Lichtenauer(University of Salzburg), P. Christian Schulze(Temple College), Sarah Eder(Paracelsus Medical University), Daniel Kretzschmar(Friedrich Schiller University Jena)
Cited by 69
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases
|European Heart Journal|2014|4.4k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k